JPH03218464A - リウマチ特異蛋白質に対する抗体 - Google Patents
リウマチ特異蛋白質に対する抗体Info
- Publication number
- JPH03218464A JPH03218464A JP24249090A JP24249090A JPH03218464A JP H03218464 A JPH03218464 A JP H03218464A JP 24249090 A JP24249090 A JP 24249090A JP 24249090 A JP24249090 A JP 24249090A JP H03218464 A JPH03218464 A JP H03218464A
- Authority
- JP
- Japan
- Prior art keywords
- gel
- electrophoresis
- mobility
- rheumatism
- rheumatoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 15
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims abstract description 19
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 abstract description 27
- 238000000034 method Methods 0.000 abstract description 16
- 239000000872 buffer Substances 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 238000001962 electrophoresis Methods 0.000 abstract description 7
- 229920001817 Agar Polymers 0.000 abstract description 5
- 239000008272 agar Substances 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229920002401 polyacrylamide Polymers 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000005406 washing Methods 0.000 abstract description 3
- 238000001502 gel electrophoresis Methods 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 abstract 3
- CWGJBBRZFIPXNZ-UHFFFAOYSA-N [C-]#N.Br Chemical compound [C-]#N.Br CWGJBBRZFIPXNZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229920000298 Cellophane Polymers 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000009666 routine test Methods 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- CJYDNDLQIIGSTH-UHFFFAOYSA-N 1-(3,5,7-trinitro-1,3,5,7-tetrazocan-1-yl)ethanone Chemical compound CC(=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 CJYDNDLQIIGSTH-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 102000001022 human rheumatoid arthritis specific protein Human genes 0.000 description 1
- 108010069045 human rheumatoid arthritis specific protein Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24249090A JPH03218464A (ja) | 1990-09-14 | 1990-09-14 | リウマチ特異蛋白質に対する抗体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24249090A JPH03218464A (ja) | 1990-09-14 | 1990-09-14 | リウマチ特異蛋白質に対する抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58053922A Division JPS59180363A (ja) | 1983-03-31 | 1983-03-31 | リウマチ特異蛋白質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03218464A true JPH03218464A (ja) | 1991-09-26 |
| JPH0541640B2 JPH0541640B2 (enrdf_load_stackoverflow) | 1993-06-24 |
Family
ID=17089863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24249090A Granted JPH03218464A (ja) | 1990-09-14 | 1990-09-14 | リウマチ特異蛋白質に対する抗体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03218464A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011033548A (ja) * | 2009-08-04 | 2011-02-17 | Hoyu Co Ltd | ２次元電気泳動方法 |
-
1990
- 1990-09-14 JP JP24249090A patent/JPH03218464A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011033548A (ja) * | 2009-08-04 | 2011-02-17 | Hoyu Co Ltd | ２次元電気泳動方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0541640B2 (enrdf_load_stackoverflow) | 1993-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saraiva et al. | Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type | |
| JPH0544478B2 (enrdf_load_stackoverflow) | ||
| Burt et al. | Liver membrane antibodies in alcoholic liver disease: 1. prevalence and immunoglobulin class. | |
| JPS6361319B2 (enrdf_load_stackoverflow) | ||
| NO303852B1 (no) | FremgangsmÕte ved pÕvisning av analyttvarianter, samt sett for utf°relse av fremgangsmÕten | |
| JPS5944321A (ja) | 新規な蛋白質およびその取得方法 | |
| JPS62501563A (ja) | リウマチ性関節炎の特徴である蛋白質 | |
| Wells et al. | Antibodies to human collagen in subjects with selective IgA deficiency | |
| EP0313156A1 (en) | SnRNP-A antigen and fragments thereof | |
| Kitamura et al. | Immunochemical analysis of the monoclonal paraprotein in scleromyxedema. | |
| JPS60104015A (ja) | 新規蛋白質ｐｐ↓２↓０およびその取得法 | |
| Patterson et al. | An IgM pyroglobulin associated with lymphosarcoma | |
| JPH03218464A (ja) | リウマチ特異蛋白質に対する抗体 | |
| US4594328A (en) | Tissue protein PP21, a process for obtaining it and its use | |
| JPH0526800B2 (enrdf_load_stackoverflow) | ||
| CN103102392A (zh) | 一种维甲酸诱导蛋白16n端多肽及其抗体的制备方法和应用 | |
| JPH0523280B2 (enrdf_load_stackoverflow) | ||
| Woo et al. | Isoelectric focusing and selectivity index in IgA nephrotic syndrome | |
| EP0190350A1 (en) | Process for preparing human proline hydroxylase | |
| McLeod et al. | 'Hypocryoglobulins': Enhanced Cryoprecipitation From Hypotonic Serum in Patients With Vasculitis | |
| JPH0666793A (ja) | リウマチ疾患のみに特異的に発現する蛋白質に対して特異な抗体 | |
| Ueda et al. | Determination of the second component of complement (C2) by electroimmunoassay in sera from patients with systemic lupus erythematosus | |
| Nagai et al. | Human prolyl hydroxylase. Purification, radioimmunoassay and clinical studies in liver diseases | |
| Oxelius | Alternating appearance of IgD and IgG myeloma protein during treatment | |
| JPS6170464A (ja) | 精製リウマチ特異蛋白質およびその特異抗体 |